Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press ... Read more
Patient enrollment is now complete for the Phase 2 clinical trial of Clene Nanomedicine‘s CNM-Au8 as a potentially disease-modifying therapy for amyotrophic lateral sclerosis (ALS). The trial, named RESCUE-ALS (NCT04098406) will ... Read more
The U.S. Food and Drug Administration has granted Prosetin orphan drug designation for the treatment of amyotrophic lateral sclerosis (ALS). Orphan drug designation grants financial incentives to companies developing medications ... Read more
Accessing and understanding insurance coverage, and paying for medical treatments and services top the list of stressors that burden people with amyotrophic lateral sclerosis (ALS) in the United States, ... Read more
A new telehealth app to help people with motor neuron diseases such as amyotrophic lateral sclerosis (ALS) connect with their healthcare providers during the COVID-19 pandemic has been fast-tracked ... Read more
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient ... Read more
Innovate UK has given a grant to Reflection Therapeutics to help fund research into new ways of protecting the nervous system from motor neuron diseases, with amyotrophic lateral sclerosis (ALS) as ... Read more